LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

被引：0

作者：

Yang, Wei ^{[1
]}

Burns, Colleen ^{[1
]}

Lindquist, Kevin ^{[2
]}

Dobkin, Julie ^{[1
]}

Shin, Hee Rae ^{[1
]}

Nguyen, Cindy ^{[1
]}

Huang, Xiaodong ^{[1
]}

Helms, Whitney ^{[3
]}

Arce, Nicholas ^{[2
]}

Mak, Yvonne ^{[2
]}

Au, Audrey ^{[1
]}

Abouzeid, Abraham ^{[4
]}

Witek, Marta ^{[4
]}

Leow, Ching Ching ^{[1
]}

Gong, Xueqian ^{[4
]}

Srinivasan, Mohan

Park, Joshua I. ^{[2
]}

Driscoll, Kyla ^{[1
]}

Hass, Andrew ^{[4
]}

Holmgaard, Rikke ^{[1
]}

Duramad, Omar ^{[2
]}

Bedard, Kristin ^{[2
]}

机构：

[1] LoxoLilly, New York, NY USA

[2] LoxoLilly, South San Francisco, CA USA

[3] LoxoLilly, Silver Spring, MD USA

[4] Eli Lilly & Co, Indianapolis, IN USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-200316

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2785 / 2786

页数：2

共 50 条

[1] ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38+malignancies
Sammicheli, Stefano
Grandclement, Camille
Dheilly, Elie
Panagopoulou, Maria
Martini, Evangelia
Suere, Perrine
Pouleau, Blandine
Estoppey, Carole
Frei, Julia
Loyau, Jeremy
Monney, Thierry
Drake, Adam
Rubod, Alain
Doucey, Marie Agnes
Menon, Vinu
Udupa, Venkatesha
Sunitha, G. N.
Rasmussen, Daniel
Olsen, Jeppe Koch
Gionannini, Roberto
Gudi, Girish
Srivastava, Ankita
Konto, Cyril
Perro, Mario
CANCER RESEARCH, 2022, 82 (12)
[2] JNJ-78306358: A first-in-class bispecific T cell redirecting HLA-G antibody
Obermajer, Natasa
Zwolak, Adam
Van de Ven, Kelly
Versmissen, Shana
Brajic, Aleksandra
Petley, Ted
Weinstock, Dan
Aligo, Jason
Yi, Fang
Jarantow, Stephen
Schutsky, Keith
Tian, Ken
Lorraine, Angelilo
Arias, Diana Alvarez
Buyens, Kristel
Torti, Vince
Menard, Krista
Rogers, Katharine
Geist, Brian
Van Heerden, Marjolein
Chu, Gerald
Verbist, Bie
Ongenaert, Mate
Hasler, Julien
Packman, Kathryn
Shenton, Jacintha
Brehmer, Dirk
Lauring, Josh
Brown, Regina J.
Greger, James
Ryan, Daphne Salick
Singh, Sanjaya
Lorenzi, Matthew V.
Lenox, Laurie
Laquerre, Sylvie
CANCER RESEARCH, 2022, 82 (12)
[3] ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
Grandclement, C.
Estoppey, C.
Dheilly, E.
Panagopoulou, M.
Martini, E.
Labanca, V.
De Angelis, S.
Frei, J.
Drake, A.
Rubod, A.
Gudi, G.
Udupa, V.
Olsen, J.
Giovannini, R.
Doucey, M.
Feldman, E.
Konto, C.
Srivastava, A.
Zhukovsky, E.
Perro, M.
Sammicheli, S.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A6 - A7
[4] Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
Hernandez, Genevive H.
So, John
Logronio, Kathryn A.
Kotturi, Maya F.
Kim, Won Seog
Armand, Philippe
Cheah, Chan Y.
Gopal, Ajay K.
Flinn, Ian W.
Gregory, Gareth P.
Matasar, Matthew J.
Nastoupil, Loretta J.
Diefenbach, Catherine S.
Yoon, Sung-Soo
Ku, Matthew
Qazi, Ibrahim
Leabman, Maya K.
Sison, Iris
Keyt, Bruce A.
Takimoto, Chris H.
Manley, Thomas J.
Budde, Elizabeth L.
BLOOD, 2022, 140 : 6436 - 6438
[5] Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies
Burt, Richard
Warcel, Dana
Fielding, Adele K.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 594 - 602
[6] First-in-class T cell-redirecting bispecific antibody targeting glypican-3: a highly tumor-selective antigen
Ishiguro, Takahiro
Kinoshita, Yasuko
Sano, Yuji
Azuma, Yumiko
Tsunenari, Toshiaki
Ono, Natsuki
Kayukawa, Yoko
Kamata-Sakurai, Mika
Shiraiwa, Hirotake
Kaneko, Akihisa
Frings, Werner
Komatsu, Shunichiro
Nezu, Junichi
Endo, Mika
CANCER RESEARCH, 2016, 76
[7] JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G
Obermajer, Natasa
Zwolak, Adam
van de Ven, Kelly
Versmissen, Shana
Menard, Krista
Rogers, Katharine
Petley, Ted
Weinstock, Dan
Aligo, Jason
Patel, Jaymala
Tian, Ken
Angelillo, Lorraine
Yi, Fang
Jarantow, Stephen
Schutsky, Keith
Hamuro, Yoshitomo
Arias, Diana Alvarez
Buyens, Kristel
Yao, Tsun-Wen Sheena
Torti, Vince
Brajic, Aleksandra
Geist, Brian
van Heerden, Marjolein
Chu, Gerald
Verbist, Bie
Ongenaert, Mate
Hasler, Julien
Packman, Kathryn
Shenton, Jacintha
Lenox, Laurie
Clawson, Jacalyn
Brown, Regina J.
Lauring, Josh
Greger, James G.
Brehmer, Dirk
Singh, Sanjaya
Lorenzi, Matthew, V
Laquerre, Sylvie
ISCIENCE, 2025, 28 (03)
[8] First-in-class small molecule ONC201 in b-cell malignancies.
Lee, Hun Ju
Andreeff, Michael
Benes, Cyril
Allen, Joshua E.
Schalop, Lee
Oster, Wolfgang
Wang, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia
Buie, Larry W.
Pecoraro, Joshua J.
Horvat, Troy Z.
Daley, Ryan J.
ANNALS OF PHARMACOTHERAPY, 2015, 49 (09) : 1057 - 1067
[10] PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
Lu, Haihui
Oka, Adwait
Coulson, Michelle
Polli, Joseph Ryan
Aardalen, Kimberly
Ramones, Melissa
Walker, Dana B.
Carrion, Ana
Alexander, Dylan
Klopfenstein, Matthieu
Akiyama, Masaki
Rucci, Francesca
Granda, Brian
Pastore, Alessandro
BLOOD, 2022, 140 : 3148 - 3148

← 1 2 3 4 5 →